Expert Interview
A look at the potential of S1P modulators in moderate-severe ulcerative colitis and how they might fit into the treatment paradigm
Ticker(s): ARNA, BMY, CNTBInstitution: NYU
- Assistant Professor of Medicine in the Division of Gastroenterology at NYU Grossman School of Medicine & gastroenterologist at the IBD Center at NYU Langone Health.
- Principal investigator of the institutional NYU IBD biorepository, IBD and Clostridioides difficile clinical trials; manages ~500 patients with ulcerative colitis (150 moderate-severe).
- Research focuses on IBD epidemiology, pathogenic triggers of IBD onset and flare, and ex vivo models for predicting responsiveness to IBD therapies.
Can you please detail your clinical experience and your current practice?
Could you please walk us through the UC landscape, specifically with the JAKs and the S1Ps, how often you're using them, the insurance steps required to use them, and how your patients are doing on either of those classes?
Added By: c_adminWhat did you think about the general ozanimod data package?
Added By: c_adminIs etrasimod going to have some better safety, or do you find this will just be almost like a "me too" agent to ozanimod?
Added By: c_adminIs the S1P heart rate effect a big issue in clinical practice, or is it pretty much a non-issue as you do the monitoring?
Added By: c_adminIf an S1P could win a Crohn's disease trial, is that more valuable than a UC indication, or just having both really valuable to you as a prescriber, because maybe it's a little higher bar to jump over?
Added By: c_adminIs there going to be a way to differentiate between the S1Ps?
Added By: c_adminThere's a lot of mechanisms being pursued in UC. Is there any mechanism that's really exciting to you? Is there a possibility that the S1P class has basically leapfrogged that by the time it starts to get a little uptake, something newer in the market just snaps a lot of that first line use, whether it's an oral ENTYVIO or something similar?
Added By: c_adminWas there anything relevant to the S1Ps that I might have missed that you want to touch on, that affects your practice a lot?
Added By: c_adminWhat's your general level of acceptance for the S1P class on a scale of one to 10?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
